Absci's fundamental outlook hinges on its AI-driven drug discovery platform, but current financials reveal a pre-revenue biotech in transition. Revenue has contracted sharply, with 2026Q2 revenue at $0 and TTM revenue down 38.2% year-over-year, while gross mar...
Price trend, volume and key moving averages
Trailing total returns as of 9/23/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 11, 2026 | -$0.18+5.8% vs -$0.19 | $300,000-67.4% vs $919,583 |
Q2 2026 May 7, 2026 | -$0.19+5.0% vs -$0.20 | $215,000-82.9% vs $1M |
Q2 2026 Mar 24, 2026 | -$0.23-43.8% vs -$0.16 | $650,000-51.5% vs $1M |
Q4 2025 Nov 12, 2025 | -$0.20-5.3% vs -$0.19 | $378,000-72.6% vs $1M |
Silence Therapeutics (NASDAQ: SLN - Get Free Report) and Absci (NASDAQ: ABSI - Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, profitability, institutional ownership, analyst recommendations, valuation, dividends and risk. Risk and Volatility Silence Therapeutics has a beta
Valneva (NASDAQ: VALN - Get Free Report) and Absci (NASDAQ: ABSI - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, dividends, analyst recommendations, risk and valuation. Profitability This table compares Valneva and Absci's net margins,
Absci Corporation (ABSI) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Absci Corporation is upgraded to “Buy” following positive interim Phase 1 data for ABS-201 in androgenetic alopecia [AGA]. ABS-201 demonstrated an excellent PK profile, enabling infrequent dosing [2–3 injections per 6 months] and strong safety/tolerability in SAD cohorts. Upcoming catalysts include 13-week interim proof-of-concept data in 2H 2026 and 26-week topline results in early 2027 for ABS-201 in AGA.
Benchmark ABSI against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Absci Corporation (ABSI)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $10.71 | $1.81B | -12.75 | -38.24% | -4113.68% | -62.5% | — | |
| $4.05 | $2.12B | -2.81 | 26.92% | -945.92% | -50.41% | — | |
| $30.70 | $2.29B | -21.77 | 23.29% | -20.98% | -16.37% | — | |
| $12.91 | $340.08M | -0.11 | -3% | -90.9% | -158.9% | — | |
| $164.60 | $10.25B | -126.62 | 20.32% | -31.66% | -29.89% | — | |
| $25.93 | $2.67B | -32.01 | 120.01% | -54.75% | -7.7% | — |
Absci Corporation (ABSI) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Absci Corporation (ABSI) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 11, 2026·SEC
Jun 24, 2026·SEC
Jun 24, 2026·SEC
Get notified when ABSI posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Absci Corporation (ABSI) stock FAQ — growth, dividends, profitability & financials explained
Absci Corporation (ABSI) reported $1.6M in revenue for fiscal year 2025. This represents a 24% decrease from $2.1M in 2019.
Absci Corporation (ABSI) saw revenue decline by 38.2% over the past year.
Absci Corporation (ABSI) reported a net loss of $121.1M for fiscal year 2025.
Absci Corporation (ABSI) has a return on equity (ROE) of -62.5%. Negative ROE indicates the company is unprofitable.
Absci Corporation (ABSI) had negative free cash flow of $109.0M in fiscal year 2025, likely due to heavy capital investments.
